Highlights

Total Revenue for the three months ended 30 September 2026 was US$26.114 million, up from US$17.062 million a year earlier.

The quarterly operating loss narrowed to US$2.629 million from US$9.153 million in the September 2025 quarter.

For the nine months ended September 2026, total revenue reached US$67.067 million, up from US$53.995 million in the prior corresponding period.

The filing reported negative shareholders’ Equity of US$31.037 million at 30 September 2026, versus negative US$16.650 million at 31 December 2025.

Medical technology company AVITA Medical, Inc. (ASX:AVH) sells products including RECELL and related wound-care technologies. Its US quarterly filing for the period ended 30 September 2026 shows higher revenue and Gross Profit than a year earlier, while the Business continued to report a net loss. The statutory statements also separate three-month performance from the nine-month totals, providing a broader view of the year-to-date trading pattern.

Third-Quarter Revenue Moves Higher

Total revenue for the three months ended 30 September 2026 was US$26.114 million, up from US$17.062 million a year earlier. Sales revenue accounted for US$25.862 million, with US$0.252 million in Lease revenue. Gross profit was US$21.941 million versus US$13.875 million. These numbers are recorded in thousands of US dollars in the company’s filing and are presented here in millions to distinguish the reported amounts clearly.

Losses Narrow Despite Ongoing Costs

The quarterly operating loss narrowed to US$2.629 million from US$9.153 million in the September 2025 quarter. Total operating expenses were US$24.570 million, compared with US$23.028 million previously. Sales and marketing, general and administrative, and Research and Development costs together made up those expenses. After other items and income tax, the net loss was US$6.222 million, compared with US$13.187 million a year earlier.

Nine-Month Revenue and Profit Picture

For the nine months ended September 2026, total revenue reached US$67.067 million, up from US$53.995 million in the prior corresponding period. Gross profit rose to US$55.436 million from US$44.505 million. Operating loss narrowed to US$18.287 million, while net loss was US$24.496 million, compared with US$36.966 million previously. The longer reporting window shows improvement against the previous year without indicating that the company has reached overall profitability.

Balance Sheet and Execution Remain Relevant

The filing reported negative shareholders’ equity of US$31.037 million at 30 September 2026, versus negative US$16.650 million at 31 December 2025. The company also disclosed financing arrangements and cash-balance requirements. Commercial uptake, operating spending and financing conditions remain important to future results. Revenue growth and narrowing operating losses are distinct from positive net Earnings or positive shareholders’ equity, neither of which was reported in the September quarterly statements.